INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10786752		
Filing Date		2004-02-25		
First Named Inventor	Christopher E. Bales et al.			
Art Unit		2109		
Examiner Name	Sherrod L. Keaton			
Attorney Docket Number		BEAS-01373US0		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	6697805		2004-02-24	Choquier et al.	
	2	6477543		2002-11-05	Huang et al.	
	3	6397231		2002-05-28	Salisbury et al.	
	4	7093200		2006-08-15	Schreiber et al.	
	5	7085755		2006-08-01	Bluhm et al.	
	6	6167407		2000-12-26	Nachenberg et al.	
	7	6269456		2001-07-31	Hodges et al.	
	8	7080000		2006-07-18	Cambridge	

9	7035944	2006-04-25	Fletcher et al.	
10	6185587	2001-02-06	Bernardo et al.	
11	6202066	2001-03-13	Barkley et al.	
12	6381579	2002-04-30	Gervais et al.	
13	6988138	2006-01-17	Alcom et al.	
14	7062511	2006-06-13	Poulsen	
15	5987469	1999-11-16	Lewis et al.	
16	6055515	2000-04-25	Consentino et al.	
17	6430556	2002-08-06	Goldberg et al.	
18	6466239	2002-10-15	Ishikawa	
19	6581071	2003-06-17	Gustman et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

If you wish to add additional U.S. Patent citation information please click the Add button.

Application Number		10786752		
Filing Date		2004-02-25		
First Named Inventor	Christ	Christopher E. Bales et al.		
Art Unit		2109		
Examiner Name	Sherrod L. Keaton			
Attorney Docket Number		BEAS-01373US0		

Add

	U.S.PATENT APPLICATION PUBLICATIONS Remove							
Examiner Initial*	xaminer Cite Name of Patentee or Appli				Name of Patentee or Applicant	Releva	Columns,Lines where nt Passages or Relevant Appear	
	1	20020169893		2002-11-14	Chen et al.			
	2	20030146937		2003-08-07	Lee			
	3	20020019827		2002-02-14	Shiman et al.			
	4	20020112171		2002-08-15	Ginter et ai.			
	5	20040167899		2004-08-26	Patadia et al.			
	6	20070083484		2007-04-12	McVeigh et al.			
	7	20030089617		2003-05-08	Clark et al.			
Ī	8	20060059107		2006-03-16	Elmore et al.			
	9	20020005867		2002-01-17	Gvily			

10	20020067370	2002-06-06	Forney et al.	
11	20020194267	2002-12-19	Flesner et al.	
12	20030126558	2003-07-03	Griffin	
13	20030167315	2003-09-04	Chowdhry et al.	
14	20030212766	2003-11-13	Glies et al.	
15	20040030744	2004-02-12	Rubin et al.	
16	20040030795	2004-02-12	Hesmer et al.	
17	20040078371	2004-04-22	Worrall et al.	
18	20040098467	2004-05-20	Dewey et al.	
19	20030120686	2003-06-26	Kim et al.	
20	20040167880	2004-08-26	Smith	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10786752		
Filing Date		2004-02-25		
First Named Inventor	Christopher E. Bales et al.			
Art Unit		2109		
Examiner Name	Sherrod L. Keaton			
Attornou Docket Number		DEAC 04273HON		

	21	20050021502		2005-01-27	Chen et al.			
	22	20030220963		2003-11-27	Golovinsky et al.			
	23	20010034771		2001-10-25	Hütsch et al.			
	24	20020147696		2002-10-10	Acker et al.			
	25	20030204481		2003-10-30	Lau			
	26	20030216938		2003-11-20	Shour			
	27	20050198617		2005-09-08	Kim et al.			
	28	20020087571		2002-07-04	Stapel et al.			
	29	20020120685		2002-08-29	Srivastava et al.			
	30	20020143819		2002-10-03	Han et al.			
If you wish	If you wish to add additional U.S. Published Application citation information please click the Add button. Add							
	FOREIGN PATENT DOCUMENTS Remove							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

F

E

Application Number		10786752		
Filing Date		2004-02-25		
First Named Inventor	Christ	Christopher E. Bales et al.		
Art Unit		2109		
Examiner Name	Sherr	Sherrod L. Keaton		
Attorney Docket Number		BEAS-01373US0		

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							
If you wish	n to a	dd additional Foreign	Patent Docume	ent citation	information p	please click the Add butto	n Add	-
			NON-PA	TENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тŝ	
	1							
If you wish	n to a	i dd additional non-pat	ent literature do	cument cit	tation informa	tion please click the Add	button Add	
				EXAMINE	R SIGNATU	RE		
Examiner	Signa	ature				Date Considered	1	
						formance with MPEP 609 with next communication		

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10786752		
Filing Date		2004-02-25		
First Named Inventor	Christ	Christopher E. Bales et al.		
Art Unit		2109		
Examiner Name	Sherr	Sherrod L. Keaton		
Attorney Docket Number		REAS.01373US0		

CERTIFICATION STATEMENT

Please see 3'	7 CFR	1.97 and	1.98 to make	the appropriate	selection(s):
---------------	-------	----------	--------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joseph P. O'Malley/	Date (YYYY-MM-DD)	2007-07-31
Name/Print	Joseph P. O'Malley	Registration Number	36226

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may disclosed to the Department of Justice to determine where the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.